아스트라제네카(AZN LN) 2026년 3분기(USD): 매출 162억 달러(예상치 160억 달러), 조정 EPS 2.79달러(예상치 2.59달러). 2026 회계연도 전망 확인

Announces cost-savings plan over three years, including a USD 2bln one-time restructuring charge and to deliver USD 1.5bln in annual pretax savings, which will be reinvested mainly into the pipeline of new drugs. CEO: "We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars." "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.”